Prenosis Secures $20M BARDA Contract and Series A Funding to Enhance Diagnostics and Therapeutics Prenosis has announced significant developments with a $20M contract from BARDA and $20M Series A funding, advancing their diagnostic technology.

Prenosis Secures $20M BARDA Contract and Series A Funding to Enhance Diagnostics and Therapeutics #United_States #Chicago #Prenosis #Sepsis_ImmunoScore #BARDA_Contract

New ICD-10-PCS Code Streamlines Documentation for AI Sepsis Diagnostics The release of a new ICD-10-PCS code empowers hospitals to document AI-enabled sepsis diagnostics, enhancing patient outcomes and reimbursement pathways.

New ICD-10-PCS Code Streamlines Documentation for AI Sepsis Diagnostics #United_States #Chicago #Prenosis #AI_Diagnostics #Sepsis_ImmunoScore

Bobby Reddy, Jr. Recognized in TIME's 2025 TIME100 Health List Bobby Reddy, Jr., CEO of Prenosis, Inc., has been honored in TIME's 2025 TIME100 Health List, acknowledging his contributions to healthcare innovation.

Bobby Reddy, Jr. Recognized in TIME's 2025 TIME100 Health List #United_States #Chicago #Prenosis #Bobby_Reddy #Sepsis_ImmunoScore

Revolutionary Sepsis ImmunoScore™ Validated as Cutting-Edge AI Diagnostic Tool in New Study Recent research highlights the Sepsis ImmunoScore™, a groundbreaking AI tool for diagnosing sepsis, showcasing its accuracy and predictive capabilities.

Revolutionary Sepsis ImmunoScore™ Validated as Cutting-Edge AI Diagnostic Tool in New Study #United_States #Chicago #Sepsis_ImmunoScore™ #Prenosis #AI_Diagnostics